Dermata Therapeutics, Inc.
DRMA
$1.29
$0.1210.26%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 19.79% | 40.91% | 46.68% | 39.87% | 26.50% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 16.40% | -1.01% | 80.00% | 100.00% | -93.66% |
| Change in Net Operating Assets | -303.22% | 142.51% | 43.89% | -250.49% | 311.12% |
| Cash from Operations | -28.21% | 54.38% | 47.24% | -26.55% | 28.49% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -76.65% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | 100.00% | -- | -68,387.50% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -80.99% | -- | -100.00% | 100.00% | -- |
| Cash from Financing | -77.59% | 6,203.50% | -100.28% | -123.42% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -108.79% | 195.83% | -251.82% | -1,617.48% | 342.47% |